Leader, Thoracic Oncology Program
Member, Hematology and Oncology
GRU Cancer Center
Assistant Professor of Medicine – Hematology and Oncology
Georgia Regents University
1410 Laney Walker Blvd., CN-2132
Augusta, GA 30912
Zhonglin Hao, MD, PhD is the Leader of the Thoracic Oncology Program at the GRU Cancer Center. Dr. Hao earned his MD in 1986 from the Inner Mongolia Medical College (China) and PhD in 1998 from The University of Tokyo (Japan). He finished his Internal Medicine training at Mercer University School of Medicine and his fellowship at Emory University (Atlanta). Dr. Hao is an Assistant Professor in the Division of Hematology and Oncology, Department of Medicine in the Medical College of Georgia at GRU and is a member of the Molecular Oncology & Biomarkers Program of the GRU Cancer Center. He attends the weekly lung cancer clinic in the Cancer Center.
Dr. Hao studies the molecular genetics of cancer using a variety of genomics and cell and molecular biology approaches. His research focus is on lung cancers. Dr. Hao has been characterizing the molecular changes in human non-small cell lung cancers (NSCLCs). He is currently investigating the role of the fibroblast growth factor receptor (FGFR) signal transduction cascade in the promotion of NSCLC growth. Overexpression of the FGFRs lead to accelerated tumor growth in a wide variety of cancer cell types, including lung, breast and bladder tumors. FGFR1 has been shown to drive cancer growth in 30-50% of NSCLCs. A small molecule tyrosine kinase inhibitor (ponatinib) recently approved by the FDA was shown to be a promising potent pan-FGFR inhibitor in NSCLC.
The Hao laboratory is also actively searching for new drug or drug combinations that are potentially promising in replacing traditional chemotherapy for the treatment of NSCLC as well as small cell lung cancer (SCLC). Orthotopic animal models in the nude mouse have been developed for testing of efficacy. Promising new drug or drug combinations are further carried on to animal models for preclinical evaluation using a live imaging system. They can be further tested in the phase I clinical trial unit in the GRU Cancer Center.